Eukaryotic Expression System eIF2 Modulation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The existing artificial eukaryotic expression systems face inefficiencies in translation due to defects in translation initiation, particularly in eukaryotic cells, where the polysomal profile shows abnormalities with chimeric enzymes containing catalytic domains of capping and DNA-dependent RNA polymerases, leading to suboptimal translation rates.
Innovation Solution
Inhibiting the phosphorylation or increasing the dephosphorylation of eIF2, a key regulator of translation initiation, by using chimeric proteins with catalytic domains of capping enzymes and DNA-dependent RNA polymerases, and introducing modulator polypeptides that target eIF2 kinases to downregulate their activity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If chimeric enzymes with catalytic domains of capping and DNA-dependent RNA polymerases are used, then capped mRNA molecules are generated efficiently, but translation initiation defects occur leading to suboptimal translation rates
Solution Approach 1:
The patent changes the phosphorylation state parameter of eIF2 by introducing modulator polypeptides that inhibit eIF2 kinases or enhance phosphatase activity. This parameter change restores translation initiation efficiency while maintaining the capped mRNA generation capability of the chimeric enzyme system.
Solution Approach 2:
The patent introduces modulator polypeptides as intermediary substances that mediate between the chimeric enzyme system and the translation initiation machinery. These modulators specifically target eIF2 kinases to prevent phosphorylation, thereby facilitating efficient translation initiation without interfering with the chimeric enzyme's capped mRNA synthesis function.
2Duration of action of stationary object
If poly(A) polymerase activity is added to extend poly(A) tail, then mRNA stability improves, but polysomal profile abnormalities indicate translation initiation defects
Solution Approach 1:
The patent extracts the problematic element causing translation initiation defects by identifying and targeting eIF2 kinases specifically. By removing or inhibiting these kinases through modulator polypeptides, the system maintains poly(A) tail extension benefits while eliminating the harmful effect on translation initiation.
Solution Approach 2:
The patent changes the phosphorylation parameter of eIF2 by introducing modulators that inhibit kinases or enhance phosphatase activity. This parameter change resolves the contradiction by maintaining mRNA stability through poly(A) tail extension while restoring translation initiation efficiency.
3Ease of operation
If eIF2 phosphorylation is increased to regulate translation, then translation initiation is controlled, but translation rate decreases due to translational arrest
Solution Approach 1:
Instead of increasing eIF2 phosphorylation to regulate translation (conventional approach), the patent inverts the strategy by using modulator polypeptides to decrease phosphorylation levels. This inversion restores translation rate while maintaining regulatory capability through alternative mechanisms.
Solution Approach 2:
The patent converts the harmful effect of eIF2 phosphorylation (translational arrest) into a beneficial state by introducing modulators that prevent phosphorylation. This transforms the problematic phosphorylation event into a beneficial dephosphorylated state that promotes efficient translation initiation.
Data Source
AI summary
The present invention concerns a method for expressing a recombinant DNA molecule in a eukaryotic host cell, comprising the steps of:(a) expressing or introducing at least one chimeric protein, in said host cell, wherein said chimeric protein comprises:(i) at least one catalytic domain of a capping enzyme, in particular selected in the group consisting of cap-0 canonical capping enzymes, cap-0 non-canonical capping enzymes, cap-1 capping enzymes and cap-2 capping enzymes; and(ii) at least one catalytic domain of a DNA-dependent RNA polymerase, in particular a bacteriophage DNA-dependent RNA polymerase,(b) constitutively or transiently downregulating the phosphorylation level of subunit a of translation initiation factor eIF2 (eIF2α) in said host cell.The invention also concerns an isolated nucleic acid molecule or a set of nucleic acid molecules, comprising or consisting of (1) at least one nucleic acid sequence encoding a chimeric protein comprising at least one catalytic domain of a capping enzyme; and at least one catalytic domain of a DNA-dependent RNA polymerase; and (2) at least one nucleic acid sequence downregulating the phosphorylation level of eIF2α in a eukaryotic host cell or encoding a polypeptide downregulating said phosphorylation level; and (3) optionally, at least one nucleic acid sequence encoding a poly(A) polymerase, as well as vectors, kits and cells comprising said nucleic acid molecule or set, and different uses and applications thereof.